|
EP2360164A3
(de)
*
|
2004-03-16 |
2012-01-04 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
|
ES2314743T3
(es)
|
2004-12-16 |
2009-03-16 |
Boehringer Ingelheim International Gmbh |
Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
|
|
DE602006009772D1
(de)
*
|
2005-02-23 |
2009-11-26 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
|
|
ATE453656T1
(de)
|
2005-04-15 |
2010-01-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
|
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
AR054871A1
(es)
|
2005-07-27 |
2007-07-25 |
Boehringer Ingelheim Int |
Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
|
|
ATE484499T1
(de)
*
|
2005-08-30 |
2010-10-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
|
NZ566787A
(en)
*
|
2005-09-08 |
2010-02-26 |
Boehringer Ingelheim Int |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
CA2634701C
(en)
*
|
2005-12-21 |
2014-07-29 |
Decode Genetics Ehf |
Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
|
|
EP1989191B1
(en)
*
|
2006-02-15 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
|
WO2008034859A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
EP2086991A1
(en)
*
|
2006-10-27 |
2009-08-12 |
Boehringer Ingelheim International GmbH |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
|
WO2008055870A1
(en)
*
|
2006-11-06 |
2008-05-15 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
WO2008090210A1
(en)
|
2007-01-26 |
2008-07-31 |
Boehringer Ingelheim International Gmbh |
Methods for preventing and treating neurodegenerative disorders
|
|
US7879807B2
(en)
*
|
2007-02-21 |
2011-02-01 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
KR101506935B1
(ko)
*
|
2007-04-02 |
2015-03-31 |
테라코스, 인코포레이티드 |
벤질릭 글리코시드 유도체 및 사용 방법
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
CN101790311B
(zh)
*
|
2007-08-23 |
2014-04-23 |
泰拉科斯有限公司 |
苄基苯衍生物及使用方法
|
|
PE20091211A1
(es)
*
|
2007-11-30 |
2009-09-14 |
Boehringer Ingelheim Int |
Derivados de pirazolopirimidina como moduladores de pde9a
|
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
|
UA105362C2
(en)
*
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
TWI482779B
(zh)
*
|
2008-08-22 |
2015-05-01 |
Theracos Inc |
Ｓｇｌｔ２抑制劑之結晶型
|
|
CN102149717B
(zh)
*
|
2008-08-28 |
2014-05-14 |
辉瑞大药厂 |
二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
|
|
AP2011005672A0
(en)
|
2008-09-08 |
2011-04-30 |
Boehringer Ingelheim Int |
Pyrazolopyrimidines and their use for the treatment of CNS disorders.
|
|
CN104138370A
(zh)
*
|
2009-02-13 |
2014-11-12 |
贝林格尔.英格海姆国际有限公司 |
用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
KR101921934B1
(ko)
|
2009-02-13 |
2018-11-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
|
|
LT2395983T
(lt)
|
2009-02-13 |
2020-07-10 |
Boehringer Ingelheim International Gmbh |
Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
PE20120505A1
(es)
|
2009-03-31 |
2012-05-09 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
|
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
|
WO2011039108A2
(en)
|
2009-09-30 |
2011-04-07 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
|
|
PH12012500633B1
(en)
|
2009-09-30 |
2017-12-13 |
Boehringer Ingelheim Int |
Method for the preparation of a crystalline form of 1-chloro -4- (beta -d- glucopyranos -1-yl) -2- (4-((s)- tetrahydrofuran -3- yloxy) benzyl) benzene
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
WO2011051864A1
(en)
|
2009-11-02 |
2011-05-05 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
AR079438A1
(es)
|
2009-12-09 |
2012-01-25 |
Panacea Biotec Ltd |
Derivados de azucar, composiciones farmaceuticas y sus usos
|
|
JP2013523681A
(ja)
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
|
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
PE20130400A1
(es)
|
2010-07-22 |
2013-04-10 |
Gilead Sciences Inc |
Metodos y compuestos para tratar infecciones virales por paramyxoviridae
|
|
HUE033378T2
(en)
|
2010-08-12 |
2017-11-28 |
Boehringer Ingelheim Int |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
JP2013224263A
(ja)
*
|
2010-08-19 |
2013-10-31 |
Taisho Pharmaceutical Co Ltd |
４−イソプロピルフェニルグルシトール化合物
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
EA201300522A1
(ru)
|
2010-11-02 |
2013-11-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Фармацевтические комбинации для лечения метаболических нарушений
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
|
EP2703396B1
(en)
*
|
2011-04-25 |
2016-06-22 |
Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. |
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
|
|
AU2012264736A1
(en)
|
2011-06-03 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2013038429A2
(en)
|
2011-09-13 |
2013-03-21 |
Panacea Biotec Ltd. |
Novel sglt inhibitors
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
|
BR112014027884A2
(pt)
|
2012-05-09 |
2017-06-27 |
Boehringer Ingelheim Int |
combinações farmacêuticas para tratamento de distúrbios metabólicos
|
|
WO2014161836A1
(en)
|
2013-04-04 |
2014-10-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
EA033286B1
(ru)
|
2013-04-18 |
2019-09-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способ лечения или отсрочки развития хронической болезни почек
|
|
CN104447893B
(zh)
*
|
2013-09-25 |
2018-01-23 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物及其在医药上的应用
|
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
|
CN105828815B
(zh)
|
2013-12-17 |
2020-03-27 |
勃林格殷格翰动物保健有限公司 |
猫科动物中代谢紊乱的治疗
|
|
ES2951127T3
(es)
*
|
2014-01-23 |
2023-10-18 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos
|
|
AU2015239655B2
(en)
|
2014-04-01 |
2019-10-24 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
|
NZ728804A
(en)
|
2014-09-25 |
2022-10-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
|
TWI698444B
(zh)
|
2014-10-29 |
2020-07-11 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
AU2016229982B2
(en)
|
2015-03-09 |
2020-06-18 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
|
RS66325B1
(sr)
|
2015-08-27 |
2025-01-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Tečne farmaceutske kompozicije koje obuhvataju inhibitore sglt 2
|
|
PT3349758T
(pt)
|
2015-09-16 |
2022-07-13 |
Gilead Sciences Inc |
Métodos para o tratamento de infeções pelo vírus arenaviridae
|
|
WO2017064193A1
(en)
|
2015-10-15 |
2017-04-20 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
JP7625363B2
(ja)
|
2016-11-10 |
2025-02-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、治療方法及びその使用
|
|
CN110869028B
(zh)
|
2017-03-14 |
2023-01-20 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
|
|
KR20190141747A
(ko)
|
2017-05-01 |
2019-12-24 |
길리애드 사이언시즈, 인코포레이티드 |
(S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
|
|
US10675296B2
(en)
|
2017-07-11 |
2020-06-09 |
Gilead Sciences, Inc. |
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
MX2022001029A
(es)
|
2019-07-26 |
2022-05-24 |
Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd |
Inhibidor de sglts/dpp4 y aplicación del mismo.
|
|
AU2020394498A1
(en)
|
2019-11-28 |
2022-06-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
|
CN118766947A
(zh)
|
2020-01-27 |
2024-10-15 |
吉利德科学公司 |
用于治疗SARS CoV-2感染的方法
|
|
AU2021222297A1
(en)
|
2020-02-17 |
2022-08-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
|
BR112022017189A2
(pt)
|
2020-03-06 |
2022-10-18 |
Vertex Pharma |
Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
|
|
CA3169340A1
(en)
|
2020-03-12 |
2021-09-16 |
Pavel R. Badalov |
Methods of preparing 1'-cyano nucleosides
|
|
JP7482250B2
(ja)
|
2020-04-06 |
2024-05-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノ置換カルバヌクレオシド類似体の吸入製剤
|
|
PL4157272T3
(pl)
|
2020-05-29 |
2025-10-20 |
Gilead Sciences, Inc. |
Remdesiwir do leczenia zakażeń wirusowych
|
|
JP2023531524A
(ja)
|
2020-06-24 |
2023-07-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシド類似体及びその使用
|
|
LT4204421T
(lt)
|
2020-08-27 |
2024-06-25 |
Gilead Sciences, Inc. |
Virusinių infekcijų gydymui skirti junginiai ir būdai
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
MX2024001184A
(es)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
|
|
US20240307426A1
(en)
|
2021-07-28 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
|
US20250170128A1
(en)
|
2021-12-30 |
2025-05-29 |
NEWAMSTERDAM PHARMA B.V. (Dutch Chamber of Commerce No. 5597 1946) |
Obicetrapib and SGLT2 Inhibitor Combination
|
|
US20230295172A1
(en)
|
2022-03-02 |
2023-09-21 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
US20230381101A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
WO2024184293A1
(en)
|
2023-03-06 |
2024-09-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
TW202446389A
(zh)
|
2023-04-24 |
2024-12-01 |
荷蘭商新阿姆斯特丹製藥公司 |
非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
|
|
US20240390317A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
|
WO2024240633A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|